Compare FSP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSP | MOLN |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 151.9M |
| IPO Year | 2001 | 2021 |
| Metric | FSP | MOLN |
|---|---|---|
| Price | $0.52 | $4.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 467.6K | 3.0K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $3.41 |
| 52 Week High | $1.83 | $5.36 |
| Indicator | FSP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 48.56 |
| Support Level | $0.50 | $3.56 |
| Resistance Level | $0.70 | $4.49 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.56 | 53.94 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.